Jay Bregman, co-founder of Andel, closes out our conversation by explaining the impact government programs will have on GLP-1 coverage.
Jay Bregman
Advertisement
Articles by Jay Bregman
In the second part of our conversation, Andel co-founder Jay Bregman how new GLP-1 options hitting the market will amplify existing coverage problems for the near future.
Jay Bregman, co-founder of Andel, the cost and operational complexity of covering GLP-1 medications.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
2
OTR Therapeutics Announces Collaboration with Zealand Pharma to Develop Metabolic Disease Treatments
3
The Cost of Fixing Pharma
4
Is Manufacturing Coming Home?
5
